Media coverage about CONMED (NASDAQ:CNMD) has been trending somewhat positive this week, Accern Sentiment reports. The research group ranks the sentiment of news coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. CONMED earned a coverage optimism score of 0.22 on Accern’s scale. Accern also assigned news stories about the medical technology company an impact score of 46.4842376893151 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
Here are some of the news stories that may have effected Accern’s rankings:
- $198.04 Million in Sales Expected for CONMED Co. (CNMD) This Quarter (americanbankingnews.com)
- Brokerages Anticipate CONMED Co. (CNMD) Will Announce Earnings of $0.43 Per Share (americanbankingnews.com)
- CONMED Co. (CNMD) CFO Sells $1,142,297.74 in Stock (americanbankingnews.com)
- CONMED Corporation to Present at the Leerink Partners 7th Annual Global Healthcare Conference (finance.yahoo.com)
- KeyCorp Analysts Lift Earnings Estimates for CONMED Co. (CNMD) (americanbankingnews.com)
Several research firms have recently issued reports on CNMD. BidaskClub upgraded shares of CONMED from a “strong sell” rating to a “sell” rating in a report on Tuesday, January 9th. Zacks Investment Research upgraded shares of CONMED from a “sell” rating to a “hold” rating in a report on Tuesday, November 14th. Finally, KeyCorp reiterated a “hold” rating on shares of CONMED in a research report on Friday, November 3rd. Four investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. CONMED has an average rating of “Hold” and a consensus target price of $59.00.
CONMED (NASDAQ:CNMD) last released its quarterly earnings data on Wednesday, January 31st. The medical technology company reported $0.69 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.65 by $0.04. CONMED had a return on equity of 9.15% and a net margin of 6.97%. The business had revenue of $222.60 million for the quarter, compared to analyst estimates of $212.17 million. During the same quarter in the prior year, the firm posted $0.54 EPS. The business’s quarterly revenue was up 9.1% compared to the same quarter last year. sell-side analysts anticipate that CONMED will post 2.14 earnings per share for the current year.
In other news, Director Jo Ann Golden sold 3,000 shares of the stock in a transaction that occurred on Thursday, February 1st. The stock was sold at an average price of $63.90, for a total transaction of $191,700.00. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CFO Luke A. Pomilio sold 18,023 shares of the stock in a transaction that occurred on Thursday, February 1st. The shares were sold at an average price of $63.38, for a total value of $1,142,297.74. The disclosure for this sale can be found here. Corporate insiders own 2.62% of the company’s stock.
CONMED Company Profile
CONMED Corporation is a medical technology company. The Company is engaged in the development, manufacturing and sale on a global basis of surgical devices and related equipment. The Company provides surgical devices and equipment for minimally invasive procedures. The Company’s products are used by surgeons and physicians in a range of specialties, including orthopedics, general surgery, gynecology, neurosurgery and gastroenterology.
Receive News & Ratings for CONMED Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CONMED and related companies with MarketBeat.com's FREE daily email newsletter.